In continuation of our earlier intimation dated December 16, 2025, and subsequent deferment notice dated December 22, 2025, we wish to inform you that the meeting of the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Dr Lalchandani Labs Limited approved a Rights Issue of 43,32,000 fully paid-up equity shares of face value ₹10 each, aggregating up to ₹4.33 crore (assuming full subscription). The entitlement ratio is 1:1, meaning eligible shareholders can apply for one Rights Share for every one share held on the record date of Tuesday, January 27, 2026. The issue price is ₹10 per share (same as face value, payable on application), and the issue will open on February 4, 2026 and close on February 20, 2026. Post-issue, the company's outstanding equity shares will double from 43,33,068 to 86,65,068 if fully subscribed. This follows an earlier intimation on December 16, 2025 and a deferment notice on December 22, 2025.
Eligible shareholders as on January 27, 2026 can double their shareholding by investing at ₹10 per share. The ex-date will likely see a downward price adjustment to reflect the theoretical value of rights. Existing investors who do not participate may see their effective stake diluted by 50%, though renunciation is permitted until February 17-20, 2026.